Investment
Features
FeesSafety
Academy
More
Pluang+

Compare State Street SPDR Bloomberg High Yield Bond ETF (JNK) vs Pfizer Inc (PFE) Price & Performance

State Street SPDR Bloomberg High Yield Bond ETFTrade
Pfizer IncTrade

Price performance (Past 24H)

Key statistics

State Street SPDR Bloomberg High Yield Bond ETF vs Pfizer Inc — how do they compare? State Street SPDR Bloomberg High Yield Bond ETF trades at $95.88, while Pfizer Inc trades at $26.31 (market cap $151.73B). The key difference: Pfizer Inc pays a 6.46% dividend while State Street SPDR Bloomberg High Yield Bond ETF pays none, and Pfizer Inc is trading nearer its 52-week high, State Street SPDR Bloomberg High Yield Bond ETF nearer its low. Which is the better fit depends on your goals.

JNKPFE
Sector
Fixed IncomeHealth
52-Week High
$98.19$28.56
52-Week Low
$94.66$23.60
Market Cap
$151.73B
Volume
29,869,932
Enterprise Value
$203.22B
Dividend Yield
6.46%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

State Street SPDR Bloomberg High Yield Bond ETF

JNK trades at $95.845, up 0.2% today, with a bearish technical outlook indicated by moving averages and ADX signals. Recent news highlights risks from AI-related corporate debt and rising Treasury yields, while dividend payments provide income. The ETF faces headwinds from inflation and geopolitical tensions affecting bond markets.

The outlook is cautious due to credit market risks and Fed uncertainty. Opportunities exist for yield-seeking investors, but volatility from oil prices and rate hikes poses significant risks. Monitoring economic data and corporate credit health is essential for navigating near-term performance.

Pfizer Inc

Pfizer (PFE) trades at $27.05, up 1.16% with a bullish technical signal and consistent earnings beats in recent quarters. Revenue remains stable around $62-63 billion, though net income is projected to decline in 2026. The stock shows strong profitability margins and a solid balance sheet, but faces headwinds from patent expirations and competitive pressures.

The outlook is mixed: valuation multiples appear reasonable, and analyst consensus leans hold with a $27.86 target. Key risks include execution on pipeline catalysts and margin compression. Upside depends on successful drug launches and cost management amid a challenging revenue environment.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About State Street SPDR Bloomberg High Yield Bond ETF

JNK is a major ETF tracking the Bloomberg High Yield Very Liquid Index. It provides exposure to U.S. dollar-denominated junk bonds with above-average liquidity, featuring 2026 top holdings like EchoStar, Cloud Software Group, and Carnival Corp.

Read more on JNK

About Pfizer Inc

Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.

Read more on PFE